Rex Fang & Innovation Equity Premium Income ETF vs Novavax Inc — how do they compare? Rex Fang & Innovation Equity Premium Income ETF trades at $41.66, while Novavax Inc trades at $8.22 (market cap $1.39B). Which is the better fit depends on your goals.
| FEPI | NVAX | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $49.54 | $11.19 |
52-Week Low | $38.13 | $6.22 |
Market Cap | — | $1.39B |
Enterprise Value | — | $890.94M |
Signals from Pluang's Aura AI — not financial advice
FEPI trades at $41.76, down 1.6% today, with a bearish technical signal from moving averages. The ETF generates high income through weekly covered call distributions, recently transitioning to weekly payouts. Recent dividends show consistent payments around $0.20-$0.22 per share, with one larger $0.90 distribution in April 2026. The concentrated portfolio of AI and mega-cap tech names provides QQQ-like exposure but with capped upside from call writing.
The outlook remains cautious due to NAV erosion risks from the covered call strategy limiting participation in rallies. While the 25% yield attracts income seekers, total returns have lagged broader tech indices. Key risks include high portfolio concentration and market volatility impacting premium income generation. Analyst views are mixed, balancing high yield against structural limitations.
Novavax (NVAX) trades at $8.42, down 5.5% on the day, reflecting a bearish technical trend. Despite a low P/E of 3.14 and recent earnings beats, the company reported a net loss margin of -14.73% for 2026 and negative cash flows. Analyst consensus is a 'Buy' with a $14.00 price target, but technical indicators signal selling pressure. Recent news highlights stock volatility and shareholder dissent at the AGM.
The outlook is mixed: strong valuation ratios and earnings beats offer upside potential, but persistent negative cash flow, high debt, and competitive pressures pose significant risks. Investor sentiment is cautious amid bearish technical signals and uncertain revenue sustainability beyond 2025.
Trailing returns across standard periods
FEPI provides exposure to top innovation stocks while generating monthly income. It uses a covered call strategy on high-volatility tech stocks to capture option premiums for investors.
Read more on FEPI →Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →